Practice description: MTM services and training.
Practice innovation: A campus-based MTM pharmacy was established for teaching, practice, and collaboration with community pharmacies to provide comprehensive medication reviews (CMRs) and MTM training.
Main
outcome measures: Number of collaborating pharmacies, number of patients contacted, number of CMRs conducted, and estimated cost avoidance (ECA).
Results: UW Pharmacy Cares was licensed as a Class A pharmacy (nondispensing) and signed “”business associate”" agreements with six community pharmacies. During July to December 2008, 10 faculty pharmacists completed training and 5 provided CMR services to 17 patients (5 telephonic and 12 face-to-face interviews). A total of 67 claims (17 CMRs and 50 CMR-generated claims) were submitted for reimbursement of $1,642 ($96.58/CMR case). Total ECA was
$ 54,250, averaging $3,191.19 per patient. Seven student pharmacists gained BTSA1 in vivo CMR interview Bromosporine training.
Conclusion: Interest in collaboration by community pharmacies was lower than expected; however, the campus-community practice model addressed unmet patient care needs, reduced outstanding MTM CMR case loads, increased ECA, and facilitated faculty development and training of student pharmacists.”
“The American Academy of Pediatrics (AAP) recommends that any child diagnosed with hypertension have an echocardiogram to evaluate for the presence of left-ventricular (LV) hypertrophy (LVH) and advocates that LVH is an indication to initiate or intensify antihypertensive therapy. However, there is no consensus on the ideal method of defining LVH in the pediatric population. Many pediatric cardiologists rely on wall-thickness z-score of the LV posterior wall and/or interventricular septum to determine LVH. Yet, the AAP advocates using LV mass indexed to 2.7
(LVMI2.7) a parts per thousand yen 51 g/m(2.7) to diagnose LVH. Recently, age-specific reference values for LVMI a parts per thousand yen 95 % were developed. The objective of the study was to determine the concordance between diagnosis of LVH by wall-thickness z-score and diagnosis by LVMI2.7 criteria. A retrospective chart review was performed for subjects diagnosed with hypertension at a single tertiary care center (2009-2012). Echocardiogram reports were reviewed, and assessment of Quisinostat datasheet LVH was recorded. Diagnosis of LVH was assigned to each report reviewed according to three criteria: (1) LV wall-thickness z-score > 2.00; (2) age-specific reference values for LVMI2.7 > 95th percentile; and (3) LVMI2.7 > 51 g/m(2.7). Cohen’s kappa statistic was used as a measurement of agreement between diagnosis by wall-thickness z-score and diagnosis using LVMI2.7. A total of 159 echocardiograms in 109 subjects were reviewed. Subjects included 31 females and 77 males, age 13.2 +/- A 4.4 years, and 39 (42 %) with a diagnosis of secondary hypertension. LVH was diagnosed in 31 cases (20 %) based on increased wall-thickness z-score.